Please ensure Javascript is enabled for purposes of website accessibility

2 Healthcare IPOs to Watch in 2021

By Jason Hawthorne - Feb 6, 2021 at 5:10AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Convenience is key for these promising companies.

IPOs are hot. A University of Florida professor known as "Mr. IPO" has data showing that the 48% average first-day jump in shares last year was the biggest since the halcyon days of 1999. Need more proof? The Renaissance IPO ETF, a fund that buys shares shortly after they begin trading, is up 200% since March 23, 2020. Most of the headlines were made by popular consumer companies like Airbnb or fast-growing technology companies like Snowflake. This year, there are a couple of companies in the healthcare industry that may also attract the same attention. When shares finally hit the market, they could get snatched up faster than you can say "dot-com bubble."

1. Lucira Health

How would you like to test yourself for COVID-19 at home and get results in 30 minutes? Lucira is betting that most people would really like to do that. The company's all-in-one test kit, launching in the first quarter, is the first prescription at-home coronavirus test authorized by the U.S. Food and Drug Administration (FDA). The molecular test's ability to detect the virus rivals some of the best clinical tests, accurately identifying 94% of infections and 98% of those not infected.

A man sitting at a desk in front of a computer holding a clipboard that reads "initial public offering" with the letters "IPO" highlighted.

Image source: Getty Images.

Management estimates the current market for molecular COVID-19 testing at $6 billion. The company also believes the monthly at-home testing demand was roughly 30 million tests per month in November, and will reach 50 million to 100 million tests per month this year. If Lucira can get its product approved for asymptomatic users and for over-the-counter (OTC) sales, it's not difficult to imagine an even rosier outlook. Financial projections are more difficult. The current reimbursement rates for similar tests is $50, and management believes it will have to price OTC devices at around $20 to spur consumer adoption.

Investors who are intrigued but fear the risk of a company going all-in on one product could buy shares of Jabil (JBL -0.23%) instead. The contract manufacturer will be making, packing, and shipping the devices for Lucira.

2. Oscar Health

Oscar is trying to disrupt health insurance by improving customer experience through technology. The company offers an easy-to-use app and online interface, as well as incentives like a dollar per day for hitting a steps goal. The idea is to be a health and wellness guide for its 420,000 members, allowing them to access medical records and lab reports, get recommendations for a doctor, and initiate virtual care through a totally online experience. The numbers show its strategy is working. Membership has grown 70% since 2017 and the company's net promoter score, a measure of customer loyalty, is three times the industry average. 

Google parent Alphabet (GOOG -0.27%) (GOOGL -0.21%) reportedly owns 10% of Oscar, having invested in the company through its Capital G investment group, as well as through Veerily, its health and life sciences arm. The tech giant sees the benefit that technology can bring to a broken industry. It's made investments in more than 50 healthcare companies, including Oscar rival Clover Health. Oscar's strategy has been to send members to the lowest-cost care site and expand virtual health. So far, 90% of members have created an online account and 63% of members' interactions with the healthcare system are virtual.

The company generates $2 billion in annual revenue, a 74% increase since 2017. And the growth is going to continue. The company announced last summer it will expand into four new states in 2021. Oscar filed its S-1, the registration to go public, confidentially, so prospective investors will have to wait for their opportunity to give the company a thorough exam.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Clover Health Investments, Corp. Stock Quote
Clover Health Investments, Corp.
CLOV
$2.25 (5.14%) $0.11
Alphabet Inc. Stock Quote
Alphabet Inc.
GOOGL
$2,174.75 (-0.21%) $-4.51
Jabil Circuit, Inc. Stock Quote
Jabil Circuit, Inc.
JBL
$51.09 (-0.23%) $0.12
Alphabet Inc. Stock Quote
Alphabet Inc.
GOOG
$2,181.62 (-0.27%) $-5.83
Snowflake Inc. Stock Quote
Snowflake Inc.
SNOW
$144.53 (3.93%) $5.47
Airbnb, Inc. Stock Quote
Airbnb, Inc.
ABNB
$91.41 (2.62%) $2.33

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.